Professor Mark James McKeage

MBChB, MMedSc, PhD, FRACP

Biography

Professor Mark McKeage is a physician-scientist with many years experience as research group leader (Cancer Clinical Pharmacology Research Group), practising medical oncologist, clinical trial investigator, graduate student thesis supervisor, and teacher of pharmacology, oncology and clinical medicine. He has qualifications as a medical oncology specialist (MBChB, FRACP), in postgraduate research (MMedSc, PhD) and 24 years post-PhD research experience. In his clinical work he sees both public and private patients. He has an extensive track record of research publication in the fields of cancer clinical pharmacology, combination phase I oncology clinical trials and the pharmacology and neurotoxicity of platinum-based antitumour drugs, currently standing at 115 research articles, 3557 citations and an h-index of 35 (Web of Science). To date, these include 80 research articles as first, senior and/or corresponding author, over 50 in the field of platinum drug pharmacology and toxicology, and original reports of 15 phase I oncology clinical trials. His current research seeks to understand mechanisms and develop treatments for platinum drug neurotoxicity and tumour resistance, and to improve lung cancer healthcare in New Zealand via the implementation of novel genetic testing strategies and targeted therapies.

Professor McKeage is currently Professor in the Department of Pharmacology and Clinical Pharmacology, and Co-director of the Auckland Cancer Society Research Centre at the University of Auckland. He previously he worked at The Institute of Cancer Research and Royal Marsden Hospital (London UK) and the Prince of Wales Hospital, a teaching hospital of the University of New South Wales. 

Visit the Cancer Clinical Pharmacology Group website

Selected publications and creative works (Research Outputs)

  • Cho, B. C., Obermannova, R., Bearz, A., McKeage, M., Kim, D.-W., Batra, U., ... Geater, S. L. (2019). Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 (7), 1255-1265. 10.1016/j.jtho.2019.03.002
  • Myint, K., Biswas, R., Li, Y., Jong, N., Jamieson, S., Liu, J., ... Lu, J. (2019). Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Scientific reports, 9 (1)10.1038/s41598-019-38667-8
    Other University of Auckland co-authors: Catherine Han, Stephen Jamieson, Christopher Squire
  • Tin Tin, S., McKeage, M. J., Khwaounjoo, P., Thi, A. M., & Elwood, J. M. (2018). Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer epidemiology, 57, 24-32. 10.1016/j.canep.2018.09.004
    URL: http://hdl.handle.net/2292/46202
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood
  • Dantzic, D., Noel, P., Merien, F., Liu, D. X., Lu, J., Han, H., ... Li, Y. (2018). The effects of synthetically modified natural compounds on ABC transporters. Pharmaceutics, 10 (3).10.3390/pharmaceutics10030127
  • McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., ... Xu, L. (2018). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Target Oncol, 13 (1), 89-98. 10.1007/s11523-017-0543-0
    Other University of Auckland co-authors: Michael Jameson
  • Cui, H., Zhang, A. J., McKeage, M. J., Nott, L. M., Geraghty, D., Guven, N., & Liu, J. J. (2017). Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Journal of Inorganic Biochemistry, 177, 249-258. 10.1016/j.jinorgbio.2017.04.022
  • McKeage, M., Elwood, M., Tin Tin, S., Khwaounjoo, P., Aye, P., Li, A., ... Kingston, N. (2017). EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 12 (5), 663-675. 10.1007/s11523-017-0515-4
    URL: http://hdl.handle.net/2292/36730
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood, Don Love, Phyu Aye
  • Shepherd, P., Sheath, K. L., Tin Tin, S., Khwaounjoo, P., Aye, P. S., Li, A., ... Elwood, J. M. (2017). Lung cancer mutation testing: A clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. Oncotarget, 8 (60), 101437-101451. 10.18632/oncotarget.21023
    URL: http://hdl.handle.net/2292/42053
    Other University of Auckland co-authors: Sandar Tin Tin, Don Love, Mark Elwood, Phyu Aye

Identifiers

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 2, Room 236A
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links